Hunger and satiety perception in patients with severe anorexia nervosa

The relationship between cannabis and anorexia nervosa: a scoping review

BACKGROUND

Relapse rates in Anorexia Nervosa (AN) remain high, warranting exploration of further treatments. Cannabinoid agonists are of interest as they have shown successful outcomes in the treatment of associated conditions, such as post-traumatic stress disorder. This scoping review explores the endocannabinoid system (ECS), benefits/harms/null effects of cannabinoid treatment, and harms of cannabis use in AN.

METHODS

PubMed, PsycINFO, Cochrane, and Web of Science were searched for studies published between 2010 and August 2023, with human participants that explored the ECS, cannabinoid treatment, or cannabis use, and included 1 or more keywords for both cannabis and AN in the title and or abstract. Reports describing secondary anorexia, reports not available in English, grey literature, reports combining data from AN with other conditions, and reports only reporting the prevalence of cannabis abuse/dependence were excluded. Data were extracted from 17 reports (n = 15 studies). For the ECS, outcomes included genetics such as allele expression related to the ECS, cannabinoid receptor availability, and circulating levels of endocannabinoids. For benefits/harms/null effects of cannabinoid treatment, outcomes included changes in weight, eating disorder (ED) symptoms, physical activity (PA), and hormones. For harms of cannabis use, outcomes included genetics related to cannabis use disorder and associations between cannabis use and ED symptoms.

RESULTS

Eight studies (n = 8 reports) found abnormalities in the ECS in AN including expression of related alleles, genotypes, and haplotypes, availability of cannabinoid receptors, and levels of endocannabinoids. Three studies (n = 5 reports) found benefits/harms/null effects of cannabinoid treatment. Benefits included weight gain, improved ED symptoms and reduced PA, while null effects included no changes in weight or ED symptoms, and harms included increased PA and lowered adipose hormones. Four studies (n = 4 reports) expanded upon harms of cannabis use, including genetic predispositions to cannabis use disorder, and compensatory behaviors related to cannabis use.

CONCLUSION

Limited evidence suggests that abnormalities in the ECS in AN may render cannabis a potential treatment for weight restoration and associated symptoms. Future research may wish to investigate individualized dosing approaches to maximize beneficial effects while minimizing harms. Level II Evidence: Scoping Review.

Individualisierte Therapieplanung mithilfe des Gewichtsmappings bei Anorexia nervosa

Die Anorexia nervosa ist eine seltene, schwerwiegende Erkrankung, deren Therapie bislang oft nur mäßig wirksam ist. Stagnierende Verläufe oder ein erhebliches Auf und Ab in der Gewichtsentwicklung zwischen stationären Behandlungen und dem häuslichen Transfer sind verbreitet und können stationäre Aufnahmen bzw. Wiederaufnahmen notwendig machen. Im Folgenden werden daher Techniken des Gewichtsmappings vorgestellt, die eine individualisierte Therapieplanung ermöglichen. Hierzu zählt zum einen die retrospektive Analyse des Lifecharts, in der die Gewichtsentwicklung über die Lebenspanne aufgezeigt wird und die damit Schweregrad der Essstörung, Krankheitsdauer und -verlauf sowie transdiagnostisch relevante Prozesse veranschaulichen kann. Zum anderen gehört dazu die prospektive Technik des Gewichtsmappings, die in einem standardisierten Vorgehen die individuell relevanten Gewichtsmarker erfasst und visualisiert. Diese diagnostischen Informationen können eine personalisierte Therapieplanung unterstützen, die sowohl den Zeitverlauf als auch den Schwierigkeitsgrad des Bewältigungsprozesses antizipiert. Mithilfe der Techniken des Gewichtsmanagements kann die Expositionsbehandlung zielgerichtet therapeutisch angeleitet und begleitet werden. Dabei werden die Arbeit mit Intervallmodulen und ihre Rolle für eine bewältigungsorientierte Expositionsbehandlung diskutiert.

Increased plasma asprosin levels in patients with drug-naive anorexia nervosa

PURPOSE

Asprosin is a centrally acting appetite-promoting hormone and promotes glucose production in the liver. This study is the first to investigate the difference in asprosin in the plasma between anorexia nervosa (AN) and healthy controls, and to explore the relationship between asprosin changes and plasma glucose levels and AN symptoms.

METHODS

Plasma asprosin and glucose concentrations were detected in AN patients (n = 46) and healthy control subjects (n = 47). Eating Disorder Inventory-2 (EDI-2) was used to assess subjects' eating disorder symptoms and related personality traits. The patient's concomitant levels of depression and anxiety were also measured using the beck depression inventory and beck anxiety inventory, respectively.

RESULTS

Results indicate that AN patients had a higher asprosin concentration in their plasma compared to healthy controls (p = 0.033). Among AN patients, plasma asprosin levels correlated positively with EDI-2 interoceptive awareness subscale score (p = 0.030) and negatively with duration of illness (p = 0.036). Multiple linear regression analyses showed that increases in asprosin levels (p = 0.029), glucose levels (p = 0.024) and body mass index (p = 0.003) were associated with an increase of the score of EDI-2 bulimia subscale.

CONCLUSIONS

Our findings suggest that the increase in plasma asprosin concentration in patients with AN may be a compensation for the body's energy shortage, and asprosin may be involved in the development of bulimia and lack of interoceptive awareness in AN patients.

LEVEL OF EVIDENCE

Level III, case-control analytic study.

Treating Eating: A Dynamical Systems Model of Eating Disorders

Mainstream forms of psychiatric talk therapy and cognitive behavioral therapy (CBT) do not reliably generate lasting recovery for eating disorders. We discuss widespread assumptions regarding the nature of eating disorders as fundamentally psychological disorders and highlight the problems that underlie these notions, as well as related practical problems in the implementation of mainstream treatments. We then offer a theoretical and practical alternative: a dynamical systems model of eating disorders in which behavioral interventions are foregrounded as powerful mediators between psychological and physical states. We go on to present empirical evidence for behavioral modification specifically of eating speed in the treatment of eating disorders, and a hypothesis accounting for the etiology and progression, as well as the effective treatment, of the full spectrum of eating problems. A dynamical systems approach mandates that in any dietary and lifestyle change as profound as recovery from an eating disorder, acknowledgment must be made of the full range of pragmatic (psychological, cultural, social, etc.) factors involved. However, normalizing eating speed may be necessary if not sufficient for the development of a reliable treatment for the full spectrum of eating disorders, in its role as a mediator in the complex feedback loops that connect the biology and the psychology with the behaviors of eating.